Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis (the ADAPT Randomized Clinical Trial)

S Chan, V Cornelius, S Cro, JI Harper, G Lack. JAMA Pediatr. 2020;174(1):29–37 Currently, systemic treatments for severe childhood atopic dermatitis have limited evidence and/or are unlicensed. The use of anti-IgE medication (omalizumab) has been employed for multiple forms of atopic diseases such as severe asthma and in conjunction with oral immunotherapy during trials to treat food allergy. However, no large randomized studies in childhood atopic dermatitis have been published. The objective of this study was to determine the effectiveness of omalizumab in treating severe atopic dermatitis in children. Eligible participants were children and adolescents aged 4 to 19 years of age who had severe eczema (with objective Scoring Atopic Dermatitis [SCORAD] index >40) that was unresponsive to optimum topical or systemic therapy and were living in the London, UK area. The Atopic Dermatitis Anti-IgE Pediatric Trial (ADAPT) was a single-center, double-blind, …